monophosphoryl lipid a

Small moleculeexperimental

Lipid A is a lipid component of an endotoxin held responsible for the toxicity of gram-negative bacteria. It is the innermost of the three regions of the lipopolysaccharide (LPS), also called endotoxin molecule, and its hydrophobic nature allows it to anchor the LPS to the outer membrane. While its toxic effects can be damaging, the sensing of lipid A by the immune system may also be critical for the onset of immune responses to gram-negative infection, and for the subsequent successful fight against the infection. — Wikipedia

Clinical trial activity

22 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
13
Phase 3
9
Phase 4
0

Earliest trial started May 1, 1992 (NCT00698893)

Timeline

1990s

  1. Jan 1, 1992

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1992

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 1993

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gsk208141
  • lipid a
  • lipid a
  • monophosphoryl lipid a
  • mpl
  • mpl
  • mpla
  • mpla
  • mpl-se
  • sb208141

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06449196Early Phase 1 (Phase 1)Aug 1, 2024International AIDS Vaccine Initiative, Polymun Scientific GmbH
NCT05290727N/AMar 1, 2022Instituto Universitario de Oftalmobiología Aplicada
NCT03961438Phase 1Jul 31, 2019University of Amsterdam
NCT03408262Phase 1Oct 6, 2017Imperial College London
NCT01751048Phase 1Mar 1, 2013National Institute of Allergy and Infectious Diseases (NIAID)
NCT01584115Phase 1/Phase 2 (Phase 2)Jul 1, 2012Butantan Institute, Instituto de Investigação em Imunologia
NCT01011309Phase 2Oct 1, 2009Immune Design, Infectious Disease Research Institute
NCT00806962Phase 1Nov 1, 2008LigoCyte, University of Rochester
NCT00241410Phase 1Dec 1, 2005Allergy Therapeutics
NCT00224484Phase 3Apr 1, 2004GlaxoSmithKline
NCT00224471Phase 3Dec 1, 2003GlaxoSmithKline
NCT00057330Phase 3Jan 1, 2003GlaxoSmithKline
NCT00001042Phase 1Nov 2, 1999National Institute of Allergy and Infectious Diseases (NIAID)
NCT00697931Phase 3May 1, 1997GlaxoSmithKline
NCT00698568Phase 3Oct 1, 1996GlaxoSmithKline
NCT00699764Phase 3Mar 1, 1996GlaxoSmithKline
NCT00698490Phase 1/Phase 2 (Phase 2)Aug 1, 1995GlaxoSmithKline
NCT00698087Phase 3Jan 1, 1995GlaxoSmithKline
NCT00697242Phase 3Jan 1, 1994GlaxoSmithKline
NCT00697970Phase 3Nov 1, 1993GlaxoSmithKline
Showing 20 of 22 trials
Page 1 / 2

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit121231992
National Institute of Allergy and Infectious Diseases (NIAID)Government2211999
Allergy TherapeuticsFor profit1112005
Butantan InstituteAcademic/Hospital1012012
Immune DesignFor profit1012009
Imperial College LondonAcademic/Hospital1112017
Infectious Disease Research InstituteAcademic/Hospital1112009
Instituto de Investigação em ImunologiaAcademic/Hospital1112012
Instituto Universitario de Oftalmobiología AplicadaAcademic/Hospital1112022
International AIDS Vaccine InitiativeAcademic/Hospital1112024
LigoCyteFor profit1112008
Polymun Scientific GmbHFor profit1012024
University of AmsterdamAcademic/Hospital1112019
University of RochesterAcademic/Hospital1012008
14 organizations
Page 1 / 1